PFPeptide File
Live Updates
NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·
Legal

Medical Disclaimer

Last updated: April 2026

Important — Please Read

This site provides research summaries for informational purposes only. Nothing on this site constitutes medical advice. Always consult a qualified healthcare provider before making any decisions about a compound or protocol.

Purpose of this site

The content published on peptidefile.com — including articles, compound profiles, evidence summaries, and any other materials — is provided for informational and educational purposes only. It does not constitute medical advice, medical diagnosis, or treatment recommendations.

Do not use information from this site as a substitute for professional medical advice. Always seek the guidance of a qualified physician or other licensed healthcare provider with any questions you may have regarding a medical condition or treatment.

Not a substitute for medical advice

The research summaries on this site are compiled from publicly available sources including peer-reviewed journals, clinical trial registries, and regulatory submissions. They are intended to help you understand what the published evidence says — not to guide personal medical decisions.

No doctor-patient relationship is created by reading this site. Individual responses to any compound vary substantially based on factors including health status, medications, genetics, and dosage. Only a qualified clinician who knows your full medical history can assess what is appropriate for you.

No endorsement of compounds

Peptide File does not endorse, recommend, or encourage the use of any compound, drug, or supplement discussed on this site. Many compounds covered here are research chemicals, investigational drugs, or substances not approved for human use by the FDA or equivalent regulatory bodies.

Obtaining, possessing, or using unapproved substances may be illegal in your jurisdiction. It is your responsibility to understand and comply with applicable laws.

Accuracy of information

We make reasonable efforts to ensure the information on this site is accurate and up to date. However, clinical research is a rapidly evolving field. Trial results, FDA timelines, and regulatory decisions can change. We do not guarantee the completeness, accuracy, or currency of any information published here.

Where we reference clinical trials, we cite published data. Evidence ratings reflect our interpretation of the published literature and are not endorsed by any regulatory authority or academic institution.

No affiliation

Peptide File is an independent publication. We are not affiliated with any pharmaceutical company, clinic, supplement retailer, compounding pharmacy, or research organisation. We do not receive compensation from any company for editorial coverage.

Limitation of liability

To the fullest extent permitted by law, Peptide File and its operators disclaim all liability for any harm, loss, or damage arising from reliance on information published on this site.

External links

This site may link to external sources including clinical trial registries, journal articles, and news publications. We are not responsible for the content of external sites and linking does not imply endorsement.

Contact

If you have concerns about any content on this site, please contact us at hello@peptidefile.com.